Earnings Call · Q1 FY2024·2024-05-02

Q1 24EPS +6.67%·Rev n/aQ4 23EPS 0.00%·Rev n/aQ3 23EPS -6.67%·Rev n/aQ2 23EPS +7.14%·Rev n/a⚠ consensus missing

Arbutus Biopharma Corp ABUS

Lisa Caperelli — Investor Relations

Mike McElhaugh — Interim President and Chief Executive Officer

Mike Sofia — Chief Scientific Officer

Karen Sims — Chief Medical Officer

David Hastings — Chief Financial Officer

−0.4%1d on move date−1.3% vs SPY3d+4.1%5d+5.6%

Research tier

Behavioral profile computed for 5 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more ABUS calls or request research access.

More ABUS calls Browse calls Request research access